Last reviewed · How we verify
Placebo lidocaine patches
Placebo lidocaine patches deliver no active pharmaceutical ingredient, serving as a control comparator in clinical trials to assess the true efficacy of active lidocaine therapy.
Placebo lidocaine patches deliver no active pharmaceutical ingredient, serving as a control comparator in clinical trials to assess the true efficacy of active lidocaine therapy. Used for Control arm in clinical trials evaluating lidocaine patch efficacy for neuropathic pain.
At a glance
| Generic name | Placebo lidocaine patches |
|---|---|
| Also known as | Placebo patch, lidocaine patch |
| Sponsor | University of Rochester |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Placebo patches are inert formulations designed to match the appearance and application method of active lidocaine patches but contain no lidocaine or other therapeutic agent. They are used in randomized controlled trials to distinguish genuine pharmacological effects of lidocaine from placebo response, expectation effects, and natural disease progression. Any observed benefit in the placebo group reflects non-specific therapeutic mechanisms such as the ritual of treatment, patient expectations, or spontaneous improvement.
Approved indications
- Control arm in clinical trials evaluating lidocaine patch efficacy for neuropathic pain
Common side effects
- Skin irritation or erythema at application site
- Placebo response (perceived pain relief without active ingredient)
Key clinical trials
- Lidocaine Patch and Lower Third Molar (PHASE3)
- The OBstetric Lidocaine Patch (OBLido) Trial (PHASE4)
- Lidocaine Patches in Elderly Patients With Traumatic Rib Fractures (PHASE4)
- Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children (NA)
- Lidocaine Patches Prior to Percutaneous Nerve Evaluation (PHASE2)
- Lidocaine Patches After Cesarean Section (PHASE3)
- Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain (PHASE2)
- Greater Occipital Nerve Block Value in Management of Postdural Puncture Headache (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo lidocaine patches CI brief — competitive landscape report
- Placebo lidocaine patches updates RSS · CI watch RSS
- University of Rochester portfolio CI